Role of short-term inhibition of factor Xa by FXV673 in arterial passivation: A study in a chronic model of thrombosis in conscious dogs

Journal of Cardiovascular Pharmacology

Volumn 38, Issue 2, 2001, Pages 288-297

  Rebello, Sam S ^a,e   Kasiewski, Charles J ^a   Wang, Wei ^a   Bentley, Ross G ^b   Morgan, Suzanne R ^a   Chu, Valeria ^a   Colussi, Dennis ^a   Brown, Karen ^a   Perrone, Mark H ^c   Leadley, Robert J ^d  

^a Aventis Pharmaceuticals   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c BRISTOL MYERS SQUIBB   (United States)

^d PFIZER INC   (United States)

^e SANOFI   (France)

Author keywords

Arterial passivation; Arterial thrombosis; Electrolytic injury; Factor Xa; Heparin

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; FXV 673; HEPARIN; PLACEBO; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOTTING; BLOOD VESSEL OCCLUSION; CAROTID ARTERY THROMBOSIS; CHRONIC DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOG; DRUG EFFICACY; ELECTROLYSIS; FEMALE; MALE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION;

ANIMALS; CAROTID ARTERY THROMBOSIS; CONSCIOUSNESS; CYCLIC N-OXIDES; DISEASE MODELS, ANIMAL; DOGS; FACTOR XA; FEMALE; FIBRINOLYTIC AGENTS; MALE; PYRIDINES; REGIONAL BLOOD FLOW;

EID: 0034914281     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200108000-00015     Document Type: Article

References (26)

1. The pathogenesis of coronary artery disease progression and regression
2. Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in the acute and postacute phases in patients with unstable angina pectoris
3. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction
4. Catheter coatings, blood flow, and biocompatibility
5. Evidence for a rebound coagulation phenomenon after cessation of a 4-h infusion of a specific thrombin inhibitor in patients with unstable angina pectoris
6. Effects of heparin and hirudin on thrombin generation and platelet aggregation after intrinsic activation of platelet rich plasma
7. Evaluation of a chimeric monoclonal antibody c7E3 Fab fragment directed against the platelet glycoprotein IIb/IIIa receptor for preventing ischemic complications of high-risk angioplasty
8. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Randomized efficacy study of Tirofiban for outcomes and REstenosis
9. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy
10. Heparin-induced thrombocytopenia
11. Direct thrombin inhibitors in venous thromboembolism
12. In vitro characterization of a novel factor Xa inhibitor, RPR130673
13. Antithrombotic efficacy of a direct fXa inhibitor, FXV673, in a canine model of rt-PA-induced coronary artery thrombolysis
14. Sustained inhibition of whole-blood clot procoagulant activity by inhibition of thrombus-associated factor Xa
15. Transient interruption of arterial thrombosis by inhibition of factor Xa results in long-term antithrombotic effects in baboons
16. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa
17. A synthetic inhibitor of factor Xa, DX-9065a, reduces proliferation of vascular smooth muscle cells in vivo in rats
18. Monocytes enhance the bi-directional release of type I plasminogen activator inhibitor by endothelial cells
19. Surface passivation by human albumin of plasmapheresis circuits reduces platelet accumulation and thrombus formation: Experimental and clinical studies
20. Development of non-thrombogenicity of injured rabbit aortas despite inhibition of platelet adherence
21. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery
22. Prolonged activation of prothrombin on the vascular wall after arterial injury
23. Sustained inhibition of the vessel wall-platelet interaction after deep coronary artery injury by temporary inhibition of the platelet glycoprotein IIb/IIIa receptor
24. Prevention of thrombosis and rethrombosis and enhancement of the thrombotic actions of recombinant tissue-type plasminogen activator in the canine heart by DMP728, a glycoprotein IIb/IIIa antagonist
25. Temporary and partial inhibition of platelets by SM-20302 prevents coronary artery thrombosis in a chronic canine model